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Abstract 
 
Doxorubicin, a widely used anticancer agent, exhibits antitumor activity against a wide variety of 
malignancies.  The drug exerts its cytotoxic effects by binding to and intercalating within the DNA of 
tumor and tissue cells.  However, current assays are unable to accurately determine the 
concentration of intracellular active form of doxorubicin. Thus, we have developed a high 
performance liquid chromatography (HPLC) methodology in order to quantify the concentrations 
of doxorubicin that are bound to DNA in tumors and tissues as an intracellular cytotoxic measure of 
doxorubicin exposure after administration of small molecule and nanoparticle formulations of 
doxorubicin.  The assay uses daunorubicin as an internal standard; liquid-liquid phase extraction to 
isolate bound drug; a Shimadzu HPLC with fluorescence detection equipped with a Phenomenex 
Luna C18 (2 um, 2.0 x 100 mm) analytical column; and a gradient mobile phase of 0.1% formic acid 
in water and acetonitrile.  The assay has a lower limit of quantification (LLOQ) of 10 ng/mL and is 
shown to be linear up to 3,000 ng/mL.  We demonstrated the suitability of this assay for 
doxorubicin bound to DNA in vivo by using it to quantify the doxorubicin concentration within 
tumor samples from SKOV3 and HEC1A mice obtained 72 hours after administering PEGylated 
liposomal doxorubicin (Doxil®; PLD) IV at 6 mg/kg.  
 
This HPLC assay allows for a sensitive and simple intracellular quantification of doxorubicin as 
compared to other methods and will be an important tool for future studies evaluating intracellular 
pharmacokinetics of doxorubicin and various nanoparticle carriers.   
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1: Introduction 
 
1.1 Doxorubicin and PEGylated liposomal doxorubicin (Doxil) 
 
The anthracycline class of anticancer agents consists of a tetracyclic ring system bound to an 
aminoglycoside. Of the four most common compounds found in this class, the most widely used is 
doxorubicin (Figure 1). Doxorubicin is a widely used cytotoxic anthracycline antibiotic that has 
been used in the treatment of a range of malignant tumors, including leukemia, lymphoma, stomach 
cancer, bone cancer, multiple myeloma, ovarian cancer and breast cancer, and has been an 
important chemotherapeutic agent since approval in 19741. These drugs are typically used in 
combination with other groups of drugs, each exhibiting a different mechanism of action, to 
increase tumor death and to minimize resistance. However, the clinical use of doxorubicin is limited 
by a cumulative dose-dependent cardiomyopathy, which can eventually lead to heart failure, 
ranging from 5-48% depending on dose2, and carries a mortality rate of 20–40%3. Such toxicities 
can be reduced or avoided though an administration schedule that produces low peak plasma drug 
concentrations. Despite enormous efforts in creating derivatives that are more efficacious and less 
cardiotoxic, doxorubicin remains a cornerstone anticancer agent4.  
 
Figure 1: Structure of anthracyclines in current clinical use for anticancer therapy.   
 
**Adapted from Reference 15 
 
Doxorubicin exerts its effect when it is taken up into the nucleus of cells, where it binds with high 
affinity to DNA via intercalation between base pairs5. There is good evidence to support that the 
mechanism of action of doxorubicin as a topoisomerase II inhibitor. Once doxorubicin is 
intercalated into DNA, it perturbs the re-ligation step of topoisomerase II, resulting in the formation 
of the ‘cleavable complex’6-7. Failure to repair DNA double strand breaks results in an apoptotic 
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Daunorubicin Epirubicin 
 
5 
response. Other cellular responses to doxorubicin have also emerged, including the formation of 
doxorubicin-DNA adducts8 and the inhibition of the DNA methyltransferase9. A range of several 
other diverse effects have also been mentioned, though the method of cell death remains unclear.  
 
In general, long-circulating PEGylated liposomal doxorubicin (PLD) formulations (such as Doxil©) 
offer distinct advantages over conventional doxorubicin, including reducing cardiac toxicity and 
increasing tolerability and efficacy in solid tumors10-11. The most significant advantage of PLD over 
non-PEGylated liposomal products is its much longer circulation, which results in greater uptake by 
tumor tissue (due to the leaky vasculature of tumor vessels, PLD preferentially distributes to 
tumors more than normal tissue)13-14. The toxicity profiles of both Doxil© and conventional 
doxorubicin have been thoroughly reviewed11 and the incidence of heart failure was shown to be 
lower with Doxil compared with conventional doxorubicin11-12. 
 
1.2 Doxorubicin-DNA adducts 
 
The history of discovery of anthracycline-DNA adducts has been previously reviewed in the 
literature15-16. Despite a large body of evidence that doxorubicin acts predominantly via 
intercalation, the lack of understanding of the full mechanism of action has hindered efforts to 
produce newer derivatives with higher activity and reduced side effects. Adducts were initially 
characterized in a cell-free environment, where doxorubicin-induced transcriptional blockages 
were observed at 5’ GpC sequences17. Further research in this cell-free environment revealed that 
formaldehyde was a byproduct of the reaction conditions, suggesting that formaldehyde was 
necessary for the covalent linkage with guanine18 (Figure 3). Many studies have since demonstrated 
the requirement for formaldehyde for activation of anthracyclines to form adducts in vitro18-22.  
 
This led to the structure of these adducts to be resolved by NMR and mass spectrometry18-21 (Figure 
2). The drug is linked by a single aminal covalent bond (N-C-N) to only one strand of DNA, using 
strong hydrogen-bonding interactions on the opposite strand to stabilize the duplex, from the 3’ 
amino of daunosamine to the exocyclic 2-NH2 amino of guanine18-19,21 (Figure 2A). This adduct 
stabilizes the local DNA region to such an extent that the adducts can even be detected by classical 
denaturation-based crosslinking assays23-24. These adducts have now been detected in vivo  in 
tumor cells in culture using several methods - the most direct using C14-labelled doxorubicin to 
yield C14-labelled doxorubicin-DNA complexes25-26. Increased cellular levels of formaldehyde have 
been detected in tumor cells (1.5-4.0uM) compared to normal cells28-29, suggesting the increased 
formation of adducts within tumor cells. These adducts have now been shown to be substantially 
more cytotoxic than lesions induced by topoisomerase II lesions27.  
 
The characteristics of adducts derived within the cell have not been chemically characterized, but 
some information exists from in vitro studies. These adducts are intrinsically unstable, 
demonstrating the reversibility of Schiff base complexes. Due to the aminal linkage, adducts are 
both heat and alkali labile, exhibiting a half-life of 5-40 hours in vitro at 37°C depending upon the 
site of adduct formation17,23-24,30. These adducts can be maintained for extended periods of time 
(several months) at 4°C and can remain almost indefinitely if kept in equilibrium with sufficient 
free drug at 37°C19. The conditions required for adduct formation in vitro have been examined in  
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Figure 2: Structure of doxorubicin-DNA adducts.  
 
**Adapted from Reference 15 
 
Figure 3: Schiff base reaction of doxorubicin with DNA to form doxorubicin-DNA adducts. 
 
**Adapted from Reference 26 
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several studies18-19,21,32: optimal formation at pH 7, double stranded DNA (dsDNA) is required, and 
the extent of formation dependent on both DNA and formaldehyde concentration. The overall half-
life reported recently for doxorubicin-DNA adducts in tumor cells in culture is 13 hours31. 
 
1.3 Previous concerns with methods of detection 
 
There are several publications that have reported methods of determining doxorubicin, and some 
of its metabolites33: capillary electrophoresis, laser-induced fluorescence detection, 
radioimmunoassay, high performance liquid chromatography (HPLC), fluorescence detection, 
chemiluminescence detection, electrochemical detection, and mass spectrometric detection (Table 
1). These methods each utilize a variety of pre-treatment procedures for samples, some of which 
are time-consuming solid-phase extractions. However, many of these methods also lack sensitivity 
and selectivity and require high expense or increased technical experience and capabilities. 
Further, efforts have also been hampered due to the failure to achieve chromatographic resolution 
of peaks and the high affinity of anthracyclines for cellular constituents34. The majority of these 
methods also obtain their samples from cultured cells versus from whole tissue or tumor. 
Therefore, it would be beneficial to research and develop a cost-effective, in-house, timely method 
of quantification of anthracyclines from a realistic sample from pharmacokinetic studies. 
 
1.4 Purpose of method development 
   
Many studies have measured total drug levels in solid tumors following administration of liposomal 
drugs42-46. However, most of these foundational studies do not distinguish between encapsulated 
and released (bioavailable) drug within the tumor tissue. Since only released drug is available for 
biological activity, the therapeutic effects of nanoparticle-containing doxorubicin can be correlated 
to the levels of bioavailable drug in tumor tissue versus levels of total drug measured within the 
tumor tissue. Thus, knowing the levels and rate of bioavailable drug will help in the design and  
 
Table 1: Quantitative techniques used to detect doxorubicin–DNA adducts 
 
Methodology 
Minimum 
Doxorubicin Dose 
Adducts per 
107 bp DNA 
Sample Source Reference 
Chromatography specific for 
covalently bound doxorubicin 
using an intercalator affinity 
column 
50 uM ~ 1220 Cultured cells 35 
Gene-specific and cross-linking 
assays 
7.5 uM 100 Cultured Cells 36-38 
32P DNA post-labelling 0.27 uM / 2.5 gm 
tumor 
10 Intra-tumoral 
injection into rat 
mammary 
carcinoma 
39 
14C-Doxorubicin bound to 
cellular DNA detected by decay 
counting 
1 umol / 200 gm rat 
1 uM 
70 
1 
Rat liver 
Cultured cells 
8, 27, 40-41 
**Adapted from Reference 25 
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comparison of improved nanoparticle formulations for doxorubicin-containing anticancer drugs. As 
nuclear DNA serves as the final site of action, the measurement of doxorubicin bound to DNA 
provides a good estimate of bioavailable levels of drug in vivo. Thus, we have developed a high 
performance liquid chromatography (HPLC) methodology in order to quantify the concentrations 
of doxorubicin that are bound to DNA in tumors and tissues as an intracellular cytotoxic measure of 
doxorubicin exposure after administration of small molecule and nanoparticle formulations of 
doxorubicin.  
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2: Materials and Methods 
 
2.1 Materials 
 
The following chemicals and reagents were purchased from Sigma Aldrich (St. Louis, Missouri): 
doxorubicin, daunorubicin (internal standard), acetonitrile, methanol, ethanol, genomic DNA from 
calf thymus, collagenase (type I), ammonium sulfate, and calcium chloride (≥93.0%, anhydrous, 
granular). Acetonitrile and methanol were of HPLC grade; ethanol was of analytical grade.  
 
The following chemicals and reagents were purchased from Fisher Scientific (Waltham, 
Massachusetts): Fermentas DNAseI enzyme and 10x reaction buffer, lambda DNA, and 
formaldehyde. Formaldehyde was of molecular biology grade.  
 
Ambion TE Buffer (pH 8.0) and Quant-iT PicoGreen dsDNA reagent were purchased from Life 
Technologies (Grand Island, New York). Qiagen DNeasy Blood & Tissue Kit for DNA extraction was 
purchased directly from Qiagen (Valencia, California). 
 
2.2 Procedure 
 
2.2.1 Standard & quality control stock preparation 
 
Stock solutions of doxorubicin (1 mg/mL) and daunorubicin (1 mg/mL) were solubilized using 
methanol and agitated for five minutes prior to initial use. Stock solutions were stored at -80°C 
until ready for use. Calf thymus DNA was solubilized into TE buffer (pH 8) for four hours to a final 
concentration of 0.5 mg/mL.  Stock DNA was stored in aliquots at -20°C until ready for use.  
 
2.2.2 Standard & quality control sample preparation 
 
Standard curve reactions were made in duplicate and quality control (QC) reactions were made in 
sextuplets per each doxorubicin concentration level. Standards were completed utilizing eight 
levels, ranging from 10 to 3000 ng/mL. Quality controls were run at the following levels: 20 (LLOQ), 
30, 500, and 2500 ng/mL. Each 0.5 mL reaction contained 30 ug calf thymus DNA and doxorubicin 
(by adding appropriate methanolic spiking solution) in TE buffer (pH 8).  
 
2.2.3 Mock sample preparation 
 
Reactions were made in triplicate per each doxorubicin concentration and run in parallel. Each 0.5 
mL reaction contained 30 ug calf thymus DNA, doxorubicin (ranging between 5 ng to 1500 ng), and 
0.37% formaldehyde in TE buffer (pH 8). Doxorubicin was added by adding appropriate methanolic 
spiking solution. Reactions were run at 4°C for four hours to allow for 100% conversion of all 
doxorubicin binding to DNA.  
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2.2.4 Tissue preparation & digestion 
  
Frozen tissue samples were removed and weighed into reinforced homogenization tubes filled with 
zirconium oxide beads. All samples were kept on ice during preparation. Tubes were spiked with 
PBS (pH 7.24) and homogenized using a Bertin Precellys 24 at 4°C at 5,000 rpm for no more than 
20 seconds.  
 
A 2 mg/mL collagenase suspension was created using 0.22 mg/mL calcium chloride dissolved in 
PBS (pH 7.24). Using a ratio of 1 uL of collagenase solution per 1 mg tissue, collagenase was added 
to each homogenized tissue sample. Samples were placed in a 37°C incubator with agitation at 250 
rpm for one hour.  
 
2.2.5 Doxorubicin-DNA extraction & quantification 
 
Digested tissue homogenate underwent DNA extraction using a DNeasy Blood & Tissue Kit utilizing 
a modified, optimized protocol based on the manufacturer’s instructions and those found within the 
literature. Final DNA samples were eluted into 300 uL TE buffer. DNA was quantified utilizing 
PicoGreen dsDNA fluorescent reagent using a Tecan infinite 200 fluorometer and a standard curve 
based on lambda DNA concentrations verified by microdot UV detection at 280 nm.   
 
2.2.6 Extraction Procedure 
 
Extracted DNA samples (0.5 mL) were combined with 50 units DNAseI and 10x Reaction Buffer, 
vortexing to mix completely. Samples were placed in a 37°C incubator with agitation at 250 rpm for 
fifteen minutes. Afterwards, we used liquid-liquid extraction with acetonitrile in a 2:1 ratio (1000 
uL ACN:500 uL aqueous), vortexing for five minutes to ensure adequate separation. Sufficient 
ammonium sulfate was added to each sample to saturate the solution before centrifuging to 
separate aqueous and organic layers.  
 
An aliquot of the upper layer was transferred into another tube and evaporated under nitrogen at 
45°C. The residue was reconstituted into 250 uL of Reconstitution Buffer (85:50 mobile phase A:B – 
see 2.2.8), and 10 uL of this solution was injected into the HPLC.  
 
2.2.7 HPLC instrumentation 
 
Analysis by HPLC, all from Shimadzu, was performed using a LC-20AB pump, an automatic sample 
injection system (SIL-20AC HT), and a stainless steel Phenomenex Luna C18 (2 um, 2.0 x 100 mm) 
analytical column contained in an oven (CTO-20A). The column effluent was monitored using a 
variable wavelength fluorescence detector (RF-10A XL) operated at excitation of 490 nm and 
emission of 590 nm.  
 
2.2.8 HPLC system conditions 
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A gradient mobile phase of 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in 
acetonitrile (mobile phase B) was filtered through a membrane filter (0.2 um). The oven 
temperature was 32°C, and the flow rate was 0.35 mL/min.  
 
2.2.9 Data analysis 
 
The ratio of the peak area of doxorubicin to that of the internal standard (daunorubicin) was used 
as the assay parameter. Peak area ratios were plotted against analyte concentrations, and standard 
calibration curves were obtained from least-squares linear regression analysis of the data.  
 
The linearity of the method was confirmed using classical statistical tests, that is, comparison of 
intercept with zero and correlation coefficients.  
 
2.2.10 Stability study 
 
Control mock samples were spiked to a standard concentration of doxorubicin (100 and 1000 
ng/mL) in triplicate per time point (zero, 2, 4, and 6 weeks). All samples were stored at -80°C. For 
each time point, samples were immediately assayed according to the procedure given above.  
 
2.2.11 Proof of concept study 
 
Three female nu-nu mice (non-tumored) were obtained 24 hours after administering PEGylated 
liposomal doxorubicin once (Doxil®; PLD) at 10 mg/kg intravenously. The mice were euthanized 
and their organs (liver, spleen, kidneys, brain, plasma, lungs) harvested and flash frozen before 
being stored at -80°C. Liver tissue samples were assayed according to the procedure given above.  
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3: Results 
 
3.1 Retention times and linearity 
 
Observed retention times were 6.2 and 9.6 minutes for doxorubicin and daunorubicin (internal 
standard), respectively (Figure 4).  The peak area ratio of doxorubicin over the internal standard 
varied linearly with concentration over the experimental range used (10-1000 ng/mL) (Figure 5). 
The correlation coefficients (r2) for calibration curves were equal to or better than 0.995.  
 
The linearity of this method was statistically confirmed. For each calibration curve, the intercept 
was not statistically different from zero. Furthermore, the relative standard deviation (or RSD%), 
computed by dividing the standard deviation by the mean value, ranged from roughly 0.6% to 
11.4%.  
 
Figure 4: HPLC chromatogram representation of samples.  
 
 
Time (min) 
 
Figure 5: Extraction of doxorubicin is linear across experimental range.  
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3.2 Precision and accuracy 
 
For each quality control point (30, 100, and 1000 ng/mL ), each representing a low, moderate, and 
high concentration in our validation range, the relative standard deviation was calculated, ranging 
from 0.7% to 12.4% (overall bias% range represented in Table 2).    
 
The intraday and between-day precision of the assay was assessed by performing three triplicate (n 
= 9) analyses of these same three quality control points above (30, 100, and 1000 ng/mL). Results, 
expressed as a coefficient of variation (CV%), are presented in Table 2, ranging between roughly 
4.0% and 8.8%.  
 
3.3 Recovery 
 
The extraction efficiency (recovery) was determined by the extraction of doxorubicin from mock 
samples of known concentrations (30, 100, and 1000 ng/mL) in triplicate. After extraction, the 
internal standard was added. Recovered doxorubicin concentrations were compared against 
extracted external standards. The standards were prepared with addition of stock doxorubicin and 
internal standard in a sample matrix to give concentrations equivalent to 100% recovery. The mean 
recovery was determined to be 63% ± 1.7% (n = 27) across the validated range (Table 2).   
 
3.4 Limit of quantification and limit of detection 
 
The limit of quantification was 10 ng/mL for doxorubicin. At this level, the error ranged from 4.3% 
to 12.1%. The limit of detection, representing a signal to noise ratio of 3:1, was 1.5 ng/mL for 
doxorubicin.  
 
Table 2: Summary of quality control validation.  
 
Sample 
Concentration 
30 ng/mL 100 ng/mL 1000 ng/mL 
n 9 9 9 
Curve Linear Range 
Fully validated over a range of 10 to 3000 ng/mL with linear 
regression (1 / x
2
) 
Sample Stability 
(6 week) -----
 100 – 104.72% 96.60 – 100% 
Mean Recovery 63.15 ± 5.56% 64.62 ± 2.59% 61.20 ± 3.89% 
Precision  of Recovery 
(CV%) 8.81% 4.01% 6.36% 
Accuracy (Bias %) 87.9 – 111.4% 87.6 – 98.5% 85.7 – 100.7% 
Max Difference 13.45% 7.91% 10.70% 
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Figure 6: Stability of Doxorubicin-DNA Samples Stored at -80°C.  
 
3.5 Stability 
 
The stability of doxorubicin-DNA adduct samples stored at -80°C as mock samples was determined 
at two concentrations on either end of the validation range (100 and 1000 ng/mL). The 
concentrations were expressed as a percent as compared with the concentration measured at time 
zero (relative percent retrieval). For doxorubicin-DNA adduct samples, no significant difference 
was observed between time zero and six weeks in storage at both concentrations tested (Figure 6).  
 
3.6 Proof of concept 
 
Based on the developed assay, true in vivo samples were tested, as opposed to prepared mock 
samples, in order to demonstrate the application of this method in future pharmacokinetic studies. 
Liver tissue samples (n = 3; see 2.2.11 for treatment description) were first used to evaluate intra-
sample variation (Table 3).  Samples were processed in tandem from the same liver homogenate 
and, after correcting the doxorubicin concentration for recovery and normalizing the data based on 
the amount of DNA extracted in the sample, showed limited sample variability (1.506 ng/ug ± 0.440 
ng/ug; CV% 29.2). Liver tissue samples (n = 3) were then used to evaluate inter-sample variation.  
Tissues samples run in parallel from the same liver showed that a minimum of 100 mg of tissue is 
required to limit the variability presented (1.416 ng/ug ± 0.308 ng/ug; CV% 21.7) (Table 4).  
 
Table 3: Intra-sample evaluation of doxorubicin-DNA concentration in liver of a 
female nu-nu mouse administered Doxil at 6 mg/kg IV x1 after 24 hours.  
 
 Measured Dox 
Conc. on DNA 
(ng) 
Corrected Dox 
Conc. on DNA 
(ng) 
DNA Conc. 
(ug) 
Normalized Conc. 
(ng/ug) 
Aliquot 1 12.921 21.535 12.940 1.664 
Aliquot 2 15.233 25.388 13.746 1.846 
Aliquot 3 10.285 17.141 16.977 1.009 
    1.506 ± 0.440 
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Table 4: Inter-sample evaluation of doxorubicin-DNA concentration in liver of a 
female nu-nu mouse administered Doxil at 6 mg/kg IV x1 after 24 hours.  
 
 Measured Dox 
Conc. on DNA 
(ng) 
Corrected Dox 
Conc. on DNA 
(ng) 
DNA Conc. 
(ug) 
Normalized Conc. 
(ng/ug) 
10 mg Non-detectable 
25 mg Non-detectable 
50 mg (Sample 1) 4.090 6.817 1.09 6.254 
50 mg (Sample 2) 7.695 12.825 4.73 2.711 
50 mg (Sample 3) 4.130 6.883 10.79 0.638 
100 mg (Sample 1) 8.345 13.908 12.91 1.077 
100 mg (Sample 2) 10.890 18.150 10.81 1.679 
100 mg (Sample 3) 8.575 14.291 9.59 1.490 
    1.416 ± 0.308 
 
Table 5: Doxorubicin-DNA tumor concentration at 72 hours in female SCID mice 
bearing orthotopic SKOV3 ovarian tumors administered Doxil at 6 mg/kg IV x1.  
 
 Measured Dox 
Conc. on DNA 
(ng) 
Corrected Dox 
Conc. on DNA 
(ng) 
DNA Conc. 
(ug) 
Normalized Conc. 
(ng/ug) 
Sample 1 29.357 46.598 24.44 1.907 
Sample 2 26.110 41.444 19.68 2.106 
Sample 3 27.394 43.483 19.03 2.285 
    2.099 ± 0.189 
 
Table 6: Doxorubicin-DNA tumor concentration at 72 hours in female SCID mice 
bearing orthotopic HEC1A ovarian tumors administered Doxil at 6 mg/kg IV x1.   
 
 Measured Dox 
Conc. on DNA 
(ng) 
Corrected Dox 
Conc. on DNA 
(ng) 
DNA Conc. 
(ug) 
Normalized Conc. 
(ng/ug) 
Sample 1 18.625 29.564 20.87 1.416 
Sample 2 22.293 35.386 28.36 1.247 
Sample 3 21.710 34.460 21.88 1.574 
    1.413 ± 0.164 
 
3.7 Applications in pharmacokinetic studies 
 
The HPLC method developed here for quantification of doxorubicin bound to DNA from tissue 
samples is suitable for the analysis of samples during pre-clinical pharmacokinetic studies within 
animal models. Table 5 and 6 illustrates a mock pharmacokinetic study utilizing our developed 
method to quantify doxorubicin concentrations from Doxil dosed (6 mg/kg) female SKOV3 and 
NEC1A mice after 72 hours and greater than 72 hours respectively. We observed a normalized 
intracellular concentration of 1.413 ± 0.164 ng/ug within SKOV3 tumor tissue samples, and 2.099 ± 
0.189 ng/ug within the HEC1A tumor tissue samples.  
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4:  Discussion & Conclusions 
 
With the advent of nanotechnologies, the pharmaceutical market has seen a vast growth in new 
nanoparticle formulations for chemotherapeutic agents, all with the promise that they afford an 
active targeting of tumor cells to release a chemotherapeutic payload into individual cells, as 
compared to other nanoparticles that utilize a passive targeting mechanism (such as used by 
Doxil©). While the concentration of doxorubicin has been measured by a wide variety of methods, 
few of these methods afford the knowledge of knowing how much drug has successfully entered the 
individual cells. To determine levels of the cytotoxic active form of doxorubicin, defined as the drug 
that successfully integrated with DNA to exert a mechanism of cell death, would allow for a method 
of comparison between these different nanoparticle formulations (Figure 7). Specifically, it would 
allow for the removal of additional sources of doxorubicin from a tissue sample that could 
contaminate a true intracellular sample, such as remaining blood, drug sequestered in intravascular 
spaces, and entrapped unreleased drug from its respective nanoparticle formulation.  
 
This HPLC assay allows for a sensitive and simple intracellular quantification of doxorubicin as 
compared to other methods and will be an important tool for future studies evaluating intracellular 
pharmacokinetics of doxorubicin and various nanoparticle carriers. This method has been used to 
successfully determine the levels of doxorubicin bound to DNA from organ tissue of a Doxil© dosed 
mouse (see section 3.6), proving its potential use in future pharmacokinetic studies.  
 
This method affords several advantages, including reproducibility and accuracy of the processed 
samples. The materials and automation required to perform this assay are found in most molecular 
biology and analytical chemistry facilities; as such, the entire process can be performed in-house 
without additional specific training. This process also allows for the processing of a great number of 
tubes simultaneously (up to 48 samples with current equipment). Furthermore, the stability of the 
doxorubicin-DNA samples proved to be resilient during storage (lasting at least six weeks), 
ensuring sample integrity during an extended period of time after tissue harvesting.  
 
However, like all methodologies, some limitations do exist for this assay. A correction factor of 0.63, 
based on the observed mean recovery, is utilized in order to correct for the loss of recovered 
material, and as such, reported values are best given as theoretical ranges. Also, due to the sensitive 
nature of both the doxorubicin’s stability and the aminal linkage that forms adducts, changes in the 
sample environment can interact significantly to change drug stability and recovery. The integrity 
of the DNA, and thus potential for doxorubicin quantification, that is able to be purified can also be 
affected based on the quality of the original tissue sample.  
 
In conclusion, a sensitive HPLC method has been developed and validated to quantify the levels of 
doxorubicin bound to DNA from a tissue sample. This method was based on the need to accurately 
determine the intracellular kinetics, and provide a comparison, for various nanoparticle 
formulations of doxorubicin. Furthermore, this proposed method has successfully applied to a 
realistic example study tissue sample from a mouse-based pharmacokinetic study.  
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Figure 7: Differences in Distribution within Tumor Tissue.  
As compared to other nanoparticles that utilize a passive targeting mechanism (such as used by Doxil©), new nanoparticle 
formulations (‘Nano-P’) for chemotherapeutic agents potentially afford an active targeting of tumor cells to release a 
chemotherapeutic payload into individual cells. This increased payload to individual cells would provide increased drug 
bound to DNA, which we can then measure using our proposed method, along with traditional pharmacokinetic 
measurements (plasma and tissue matrix).  
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Supplemental Figure 1: Schematic of developed HPLC assay for quantification of 
doxorubicin bound to DNA from tissue samples. 
 
 
 
 
 
